Increased bone resorption in patients with Crohn's disease
Authors: Robinson1; Iqbal2; Abrams3; Al-Azzawi4; Mayberry1
Source: Alimentary Pharmacology & Therapeutics, Volume 12, Number 8, August 1998 , pp. 699-705(7)
Publisher: Blackwell Publishing
Abstract:
Background: Patients with Crohn's disease are at risk of osteoporosis and premature fracture. However, the pathophysiology underlying bone loss remains poorly understood and the optimum treatment has not been established. Aim: To investigate mechanisms of bone loss in Crohn's disease using biochemical markers of bone turnover. Methods: Bone mineral density was measured at the hip and spine using dual-energy X-ray absorptiometry in 117 patients (48 male) with Crohn's disease. Bone turnover was assessed by measuring serum osteocalcin (BGP), pro-collagen carboxy-terminal propeptide (PICP), bone specific alkaline phosphatase (BALP) and urinary deoxypyridinoline (DPD); and compared to age-matched healthy controls (n = 28). Results: Bone mineral density was reduced (z-score < −1) in 48 (41%) patients with Crohn's disease. Mean values for bone formation markers in patients with Crohn's disease were all within the normal reference range (BGP 8.92 (± 3.23) ng/mL (normal range 3.4-10.0), BALP 17.6 (± 12.6) U/L (normal range 11.6-43.3), PICP 95.1 (± 46.5) ng/mL (normal range 69-163)) and were not significantly different to the control population. However, mean urinary DPD was significantly higher in patients with Crohn's disease compared to healthy controls (10.97 (± 9.22) nM DPD/mM creatinine vs. 5.02 (± 1.03) nM DPD/mM creatinine, difference in means = 5.95, 95% CI: −9.6 to −2.3, P = 0.00001) and compared to the UK reference range DPD levels were increased in 74 (63%) patients. Conclusions: Bone resorption as evidenced by urinary DPD was frequently increased in patients with Crohn's disease and was significantly higher than in an age-matched control population. The high levels of urinary DPD suggest increased bone collagen degradation may contribute to osteoporosis in patients with Crohn's disease. These results suggest anti-resorptive agents such as the bisphosphonates may be effective treatment for osteoporosis in Crohn's disease.Document Type: Original article
DOI: 10.1046/j.1365-2036.1998.00364.x
Affiliations: 1: Gastrointestinal Research Unit, Leicester General Hospital, 2: Department of Clinical Chemistry, Leicester Royal Infirmary, 3: Department of Epidemiology and Public Health, University of Leicester, 4: Department of Obstetrics & Gynaecology, Leicester Royal Infirmary, Leicester, UK

Click here for Page Help